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Strengths and limitations of this study
 ► A nationally representative sample of 109 551 
Chinese adults were included, which increases the 
validity of the study.
 ► We compared three different definitions of meta-
bolic syndrome (MetS)—the updated International 
Diabetes Federation, National Cholesterol Education 
Program Adult Treatment Panel III and American 
Heart Association/National Heart, Lung, and Blood 
Institute—to evaluate the association between 
MetS and coronary heart disease, stroke and atrial 
fibrillation.
 ► A limitation is the lack of longitudinal data, which 
could create causal inference.
AbStrACt
Objectives To assess the relationship between metabolic 
syndrome (MetS) and its components and cardiovascular 
disease (CVD) according to different criteria of MetS, as 
well as whether the estimated association between MetS 
and CVD was affected by different definitions of MetS 
among the Chinese population.
Design Population-based, cross-sectional study.
Setting Data were from a large-scale national stroke 
screening survey, China National Stroke Screening and 
Prevention Project.
Participants A nationally representative sample of 
109 551 Chinese adults aged ≥40 years in 2014–2015 
were included.
Primary outcome measures CVD conditions (stroke, 
coronary heart disease (CHD) and atrial fibrillation (AF)) 
diagnosed by clinicians were self-reported.
results ORs after adjusting for CHD, stroke, AF and 
CVD in those with MetS using the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III) 
criterion were 1.56 (95% CI 1.48 to 1.63), 1.23 (95% CI 
1.17 to 1.30), 1.14 (95% CI 1.08 to 1.21) and 1.40 (95% 
CI 1.35 to 1.45); 1.51 (95% CI 1.44 to 1.58), 1.20 (95% CI 
1.14 to 1.26), 1.09 (95% CI 1.04 to 1.15) and 1.34 (95% CI 
1.29 to 1.38) with the American Heart Association/National 
Heart, Lung, and Blood Institute criterion; and 1.41 (95% 
CI 1.35 to 1.48), 1.24 (95% CI 1.19 to 1.30), 1.12 (95% 
CI 1.06 to 1.18) and 1.31 (95% CI 1.27 to 1.35) with the 
International Diabetes Federation criterion, respectively. 
Elevated blood pressures were all highly related to the 
prevalence of stroke and AF, and reduced high-density 
lipoprotein-cholesterol was associated with a higher OR for 
CHD than other individual components of MetS.
Conclusions MetS is significantly associated with CVD, 
and the prevalence of CVD was more evident when MetS 
was defined according to the NCEP ATP III criterion. 
Developing effective public health strategies for the 
prevention, detection and treatment of MetS should be an 
urgent priority to reduce the burden of CVD in China.
bACkgrOunD
Cardiovascular disease (CVD) mortality has 
been declining in most Western countries 
since the 1980s.1–4 However, CVD morbidity 
and mortality have been increasing in 
China,5–8 with an estimated 21 million 
additional CVD cases by 2030.9 Metabolic 
syndrome (MetS) refers to a cluster of cardio-
vascular risk factors, including abdominal 
obesity, elevated blood pressure (EBP), 
dyslipidaemia and dysglycaemia, which are 
associated with the development of CVD10 
and increased risk of mortality from CVD and 
all causes.11–13
Previous studies have explored the effects 
of MetS on the risk of CVD in different popu-
lations, but the results were inconsistent. 
A study based on two prospective cohorts14 
showed that MetS and its components had 
weak or no associated risk of CVD in elderly 
populations using the National Cholesterol 
Education Program Adult Treatment Panel III 
(NCEP ATP III) definition, and a meta-anal-
ysis of 37 longitudinal studies showed only 
a modest relative risk among patients with 
MetS for CVD.15 However, MetS was associ-
ated with a twofold increase in age-adjusted 
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risk for fatal CVD in men and non-fatal CVD in women in 
a Dutch population-based cohort study.16
Only a few population-based studies were conducted 
in China with regard to the association between MetS 
and CVD. A cross-sectional study17 suggested that MetS, 
as defined by the revised NCEP ATP III criterion, was 
associated with coronary heart disease (CHD). Another 
cross-sectional study18 of 2334 elderly in an urban commu-
nity in Beijing in 2001–2002 showed that MetS was associ-
ated with the prevalence of CHD, stroke and peripheral 
arterial disease using the NCEP ATP III and the updated 
International Diabetes Federation (IDF) criteria.
MetS can be defined using different criteria, which 
inevitably led to substantial confusion and absence of 
comparability between studies. Different definitions 
also have their applicability to different ethnic groups, 
such as in terms of obesity cut-offs.19 However, it is still 
unclear which definition of MetS is the most suitable 
for use in the Chinese population. In the present study, 
we used data from a large-scale, national cross-sectional 
study to compare three different definitions of MetS—
updated IDF, NCEP ATP III and American Heart Associ-
ation/National Heart, Lung, and Blood Institute (AHA/
NHLBI)—to evaluate the association between MetS and 
CHD, stroke and atrial fibrillation (AF). We also investi-
gated to what extent the individual components of MetS 
and their occurrence in pairs or triplets or quartets were 
associated with CVD in Chinese middle-aged and elderly 
populations, as well as whether the estimated association 
between MetS and CVD was affected by different defini-
tions of MetS.
MethODS
Study subjects and design
We used data from a large-scale, national stroke screening 
survey, China National Stroke Screening and Preven-
tion Project (CNSSPP). The survey was administrated 
by the National Project Office of Stroke Prevention and 
Control and carried out in 30 provinces (not including 
the province of Tibet) in China from October 2014 to 
November 2015; the rationale, design and methods have 
previously been described in detail.20 21 Briefly, a total of 
200 project areas were first selected in proportion to the 
local population size and the number of countries using 
a two-stage stratified cluster sampling method. Then an 
urban community and a rural village were selected from 
each project area as primary sampling units according 
to geographical locations and suggestions from local 
hospitals. The cluster sampling method was used in every 
primary sampling unit, and all residents aged ≥40 years 
were surveyed during the primary screening. Question-
naire completion, physical examination and the assess-
ment of risk factors of stroke were conducted in primary 
healthcare institutions, and the data were collected by 
trained medical staff using a standardised questionnaire in 
order to control for potential sources of bias. In addition, 
a sample of study participants were randomly selected in 
each primary sampling unit for further laboratory tests, 
carotid ultrasound and ECG. The analysis on MetS was 
restricted to individuals who had completed all surveys 
and examinations. A total of 726 451 participants were 
included in the CNSSPP survey in the CNSSPP survey, 
and 109 551 of them who received additional laboratory 
tests with a complete data on MetS and all the covariates 
were included in the present study. Participants could 
obtain the results from the primary healthcare institu-
tions 2 weeks later.
Definition of MetS
The first definition of MetS was the updated IDF defini-
tion. The updated IDF defines MetS as central obesity 
(waist circumference ≥90 cm in men and ≥80 cm in 
women) plus any two of the following four additional 
factors: (1) hypertriglyceridaemia triglyceride level 
≥1.7 mmol/L; (2) high blood pressure ≥130/85 mm Hg 
or treatment of previously diagnosed hypertension; (3) 
reduced high-density lipoprotein (HDL)-cholesterol 
<1.03 mmol/L in men and <1.29 mmol/L in women, or 
specific treatment for these lipid abnormalities; and (4) 
hyperglycaemia fasting glucose level of ≥5.6 mmol/L or 
treatment of previously diagnosed type 2 diabetes.
The second definition of MetS was the NCEP ATP III 
definition. A person was deemed to have MetS when 
three or more of the following five criteria were met: the 
criteria for high blood pressure, hypertriglyceridaemia 
and reduced HDL cholesterol were the same as those 
of the IDF, but the central obesity was defined as waist 
circumference ≥102 cm in men and ≥88 cm in women, 
and hyperglycaemia was defined as fasting glucose level of 
≥6.1 mmol/L or treatment of previously diagnosed type 2 
diabetes.
The third definition of MetS was the AHA/NHLBI 
definition. A person was considered to have MetS when 
three or more of the following five criteria were satisfied: 
waist circumference, high blood pressure, hypertriglyce-
ridaemia and reduced HDL cholesterol were defined 
as those of the NCEP ATP III, but hyperglycaemia was 
defined as a fasting glucose level of ≥5.6 mmol/L or previ-
ously diagnosed type 2 diabetes.
Diagnosis of CVD
CVD conditions (stroke, CHD and AF) in the current 
study were based on participants’ self-reports of these 
diseases as diagnosed by clinicians.
Covariates
Data on sociodemographic characteristics (age, gender, 
education and marital status), lifestyle, history of chronic 
diseases and physical activity were collected through 
face-to-face interviews by trained researchers. People 
who smoke at least one cigarette per day for more than 
half a year were defined as current smokers, and those 
who drink once or more per week for more than half a 
year were defined as current drinkers. Adequate physical 
activity was defined as regular exercise for more than three 
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times per week and at least 30 min each time, or engaged 
in heavy physical work. Family history of chronic diseases 
diagnosed by a physician was self-reported, including 
hypertension, diabetes mellitus, CHD and stroke.
Data analysis
The t-test and χ2 test were used to analyse continuous and 
categorical variables, respectively. Logistic regressions 
were used to calculate ORs and their 95% CIs. Potential 
confounders (age (40–49, 50–59, ≥60), gender (male, 
female), marital status (married, single or divorced, 
widowed), level of education (primary school and below, 
middle school, high school or the equivalent, university 
or other tertiary degree), currently smoking (yes, no), 
currently drinking (yes, no), physical activity (yes, no), 
and family histories of CVD (yes, no) and diabetes mellitus 
(yes, no)) were adjusted. All analyses were conducted 
using SPSS V.19.0.
Patient and public involvement
This analysis is of secondary data collected 5 years ago, and 
accordingly the participants included were not involved 
in the conceptualisation or design of our specific study.
reSultS
The present study used data from 109 551 participants 
(aged ≥40 years) who received clinical examinations. 
Table 1 shows the basic characteristics of the 109 551 
subjects (49 789 men and 59 762 women). Except for 
body mass index and fasting glucose, statistically signif-
icant differences were found between men and women 
in other demographic, anthropometric and clinical 
characteristics.
Table 2 shows the estimated association between 
different CVD conditions and MetS or components of 
MetS by different definitions. It showed in all MetS criteria 
that MetS was significantly associated with the prevalence 
of CHD, stroke and AF. However, the ORs for CVD asso-
ciated with MetS defined by NCEP ATP III seemed to 
be stronger than those associated with MetS defined by 
other criteria. We also calculated the prevalence of CVD 
by sex, and the adjusted ORs of CVD based on MetS 
defined by NCEP ATP III criterion were 1.43 (95% CI 
1.35 to 1.51) for men and 1.39 (95% CI 1.33 to 1.45) for 
women. Overall, the number of MetS components was 
positively associated with a higher prevalence of CVDs. 
A significantly higher prevalence of CHD, stroke, AF and 
CVD with an increasing number of MetS components was 
also found based on the three criteria (figure 1).
The effects of various combinations of MetS traits on 
the three conditions according to the presence of a single 
component and their combination in pairs, triplets and 
quartets are shown in online supplementary table 1. The 
risk for conditions associated with specific trait combina-
tions was estimated with the group without that specific 
combination used as the comparator. The analysis 
suggested heterogeneity in the distribution of the various 
trait combinations that make up MetS and the associ-
ated heterogeneity in the risk for conditions. In terms of 
a single component from all criteria, low level of HDL 
cholesterol was associated with the highest OR for CHD 
(OR, 1.75, 95% CI 1.67 to 1.83), and EBP was associated 
with the highest ORs for stroke (OR, 1.95, 95% CI 1.84 
to 2.07), AF (OR, 1.35, 95% CI 1.27 to 1.43) and CVD 
(OR, 1.56, 95% CI 1.50 to 1.62). The analyses based on 
different combinations of two, three and four MetS traits 
were more informative, and the results indicated that 
the ORs for CHD and CVD were higher in the combina-
tions that included reduced HDL-cholesterol than other 
combinations, and the combinations that included EBP 
were all highly related to the ORs for stroke and AF.
DiSCuSSiOn
In the present study, subjects with MetS defined by any 
of the three criteria had an increased prevalence of CHD 
and stroke. Many studies14 15 have been conducted in 
other populations to examine the associations between 
MetS and CHD or stroke, and the results were controver-
sial. Using the modified NCEP criteria, Shaista Malik et al22 
showed CHD, CVD and total mortality were significantly 
higher in US adults aged 30–74 with MetS than in those 
without. However, results from the Prospective Study of 
Pravastatin in the Elderly at Risk (PROSPER) and British 
Regional Heart Study (BRHS) studies suggested weak or 
no association was found between MetS and vascular risk 
in elderly populations using the NCEP ATP III defini-
tion.14 The NCEP ATP III definition of MetS was associ-
ated with a twofold increase in age-adjusted risk for fatal 
CVD in men and non-fatal CVD in women in a Dutch 
population-based cohort study, and the cohort study 
also showed MetS was associated with different increased 
risks of incident cardiovascular morbidity and mortality 
in European population when different definitions were 
used.16 Thus, the results of the studies may be different 
when using different definitions of MetS or conducted 
in different populations. The results of our study were in 
compliance with a previous study conducted in a Chinese 
population,18 and the association seemed to be stronger 
in men than in women.
As far as we know, there are currently no convincing data 
on the association between MetS and AF in the Chinese 
population. AF is the most common arrhythmia in clin-
ical practice and is associated with an increased risk of 
ischaemic stroke, heart failure and overall mortality.23–26 
A recent study27 in 47 countries reported that the second 
highest number of stroke occurred in patients with AF 
in China. The components of MetS are also risk factors 
for the development of AF.28 29 A prospective, communi-
ty-based cohort study in Japan showed that the association 
between MetS and AF remained significant in subjects 
without treated hypertension using the NCEP ATP III 
definition (HR, 1.78) but not using the AHA/NHLBI 
definition (HR, 1.28).30 Another study conducted in the 
USA suggested that in non-diabetic patients with essential 
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Table 1 Demographic, anthropometric and plasma biochemical characteristics of subjects
Characteristics Male (n=49 789) Female (n=59 762) P value
Mean age (mean, SD) 59.15±11.150 59.30±10.894 0.028
Age
  40–49 11 842 (23.8) 13 095 (21.9) <0.001
  50–59 13 872 (27.9) 17 504 (29.3)
  ≥60 24 075 (48.4) 29 163 (8.8)
Education
  Primary school and below 17 504 (35.2) 28 786 (8.2) <0.001
  Middle school 9277 (38.7) 19 018 (31.8)
  High school or the equivalent 8339 (16.7) 8623 (14.4)
  University or other tertiary degree 4669 (9.4) 3335 (5.6)
Marital status
  Married 47 467 (95.3) 54 729 (91.6) <0.001
  Single or divorced 1001 (2.0) 844 (1.4)
  Widowed 1321 (2.7) 4189 (7.0)
Physical activity* 37 637 (75.6) 44 241 (74.0) <0.001
Smokers 21 378 (42.9) 2196 (3.7) <0.001
Drinkers 13 581 (27.3) 1485 (2.5) <0.001
Coronary heart disease 3238 (6.5) 5111 (8.6) <0.001
Atrial fibrillation 2553 (5.1) 3961 (6.6) <0.001
Stroke 4617 (9.3) 4432 (7.4) <0.001
Hypertension 21 688 (43.6) 26 165 (43.8) <0.001
Diabetes mellitus 6799 (13.7) 9000 (15.1) <0.001
Family history of stroke 7131 (14.3) 9083 (15.2) <0.001
Family history of coronary heart disease 2885 (5.8) 4448 (7.4) <0.001
Family history of hypertension 9148 (18.4) 11 499 (19.2) <0.001
Antihypertension medication in 2 weeks 13 659 (27.4) 16 811 (28.1) 0.010
Antidiabetic medication in 2 weeks 4282 (8.6) 5663 (9.5) <0.001
Body mass index (mean, SD) 24.87±3.520 24.90±3.809 0.306
Waistline (mean, SD) 87.55±10.45 84.19±10.45 <0.001
Waist circumference (cm) (NCEP ATP III and AHA/NHLBI)† 3608 (7.2) 20 215 (33.8) <0.001
Waist circumference (cm) (IDF)‡ 19 964 (40.1) 40 999 (68.6) <0.001
Systolic blood pressure (mm Hg) 134.94±18.47 134.00±19.85 <0.001
Diastolic blood pressure (mm Hg) 83.23±11.30 81.44±11.21 <0.001
Triglycerides (mmol/L) 1.76±1.36 1.73±1.18 0.003
Total cholesterol (mmol/L) 4.77±1.09 5.01±1.15 <0.001
HDL cholesterol (mmol/L) 1.43±0.61 1.50±0.57 <0.001
LDL cholesterol (mmol/L) 2.80±0.93 2.92±0.97 <0.001
Fasting glucose (mmol/L) 5.76±1.76 5.75±1.77 0.292
Fasting glucose (mmol/L) (NCEP ATP III)§ 11 353 (22.8) 13 242 (22.2) 0.011
Fasting glucose (mmol/L) (AHA/NHLBI and IDF)¶ 19 846 (39.9) 23 158 (38.8) <0.001
*Physical activity ≥3 per week and ≥30 min each time, or the person works in non-industrial/agriculture labour.
†Waist circumference ≥102 cm in men and ≥88 cm in women.
‡Waist circumference ≥90 cm in men and ≥80 cm in women.
§Fasting glucose level of ≥5.6 mmol/L.
¶Fasting glucose level of ≥6.1 mmol/L.
AHA, American Heart Association; HDL, high-density lipoprotein; IDF, International Diabetes Federation; LDL, low-density lipoprotein; NCEP 
ATP III, National Cholesterol Education Program Adult Treatment Panel III; NHLBI, National Heart, Lung, and Blood Institute.
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Figure 1 ORs of MetS with different numbers of 
components according to the three definitions of MetS 
among patients with CHD, stroke or AF. AF, atrial fibrillation; 
AHA, American Heart Association; CHD, coronary heart 
disease; CVD, cardiovascular disease; IDF, International 
Diabetes Federation; MetS, metabolic syndrome; NCEP ATP 
III, National Cholesterol Education Program Adult Treatment 
Panel III; NHLBI, National Heart, Lung, and Blood Institute.
hypertension, MetS is directly and independently related 
to the prevalence of AF. Our study indicated that MetS 
was associated with the prevalence of AF using three defi-
nitions, which supported previous studies conducted in 
other countries.
In addition, we conducted further analyses to explore 
which component or combinations of MetS were associ-
ated with the three conditions. The results showed that 
subjects with low HDL cholesterol had the highest OR for 
CHD and individuals with EBP had the highest risk for 
stroke, AF and CVD. In addition, hypertriglyceridaemia 
was associated with an increased prevalence of CHD, but 
not stroke or AF, and low HDL cholesterol was not associ-
ated with AF. The differences in associations of MetS traits 
with these diseases may be due to the different pathology 
mechanisms, and these findings suggested priority risk 
factors that should be considered for the prevention 
and management of different diseases. Moreover, we 
also found that subjects with different trait combinations 
had diverse prevalence of diseases. For example, subjects 
with low HDL cholesterol and hyperglycaemia (glucose 
≥6.1 mmol/L) had a higher OR for CHD than other pairs, 
and those with low HDL cholesterol and hyperglycaemia 
(glucose ≥6.1 mmol/L) and hypertriglyceridaemia (and 
central obesity (waist ≥90/80 cm)) had the highest OR 
for CHD among triplets (quartets). These findings indi-
cated that low HDL cholesterol was the most important 
risk factor for CHD. Similarly, EBP was an important 
risk factor for stroke and AF. In addition, our study also 
showed that more MetS components were associated 
with a higher risk of diseases. Thus, doctors and patients 
should pay more attention on the populations with multi-
components of MetS.
Several expert groups such as the IDF and the ATP 
III have proposed definitions of MetS. However, there 
is a lack of universally accepted definition around the 
world.31 32 Although all the existing definitions include 
obesity, hypertension, hyperglycaemia and dyslipi-
daemia, there are still differences in details and criteria, 
and controversy remains on how to define the cut-off 
points for each component of the cluster and the way of 
combining them. Therefore, it is necessary to examine 
the relationship between individual components of MetS 
or their cut-offs and CVD to develop a practical and gener-
ally accepted definition of MetS. Our study showed that 
the odds for CVD were higher when the NCEP ATP III 
definition was used than when the updated IDF or AHA/
NHLBI definition was used. Thus, the NCEP ATP III defi-
nition may be recommended to estimate the risk of CVD 
based on the present data. Our results were inconsistent 
with Frank B Hu’s study,18 which indicated that the IDF 
criterion seemed to be better than the NCEP ATP III crite-
rion. The different types of CVD may contribute to the 
explanation, as peripheral arterial disease was included 
as CVD in that study. Further studies that include more 
CVDs should be conducted in the future.
This study is a national study with a large sample size 
that aimed to examine the association between MetS and 
the prevalence of CHD and stroke, as well as the first study 
on the association between MetS and the prevalence of 
AF in the Chinese population, which will contribute to 
confirming the associations between MetS and different 
CVD conditions. It is reported that AF will become an 
increasingly significant burden in developing countries, 
and the prevalence of AF in those aged over 60 was esti-
mated to rise from 3.9 million to 9 million by 2050 in 
China.33 Our study revealed that the risk of AF may be 
deceased by 10% if MetS could be prevented and EBP 
controlled. In addition, our study also indicated that low 
HDL cholesterol and EBP had the strongest associations 
with the risk of CVD, and findings on the relationships 
between MetS individual component and their combina-
tions in pairs or triplets or quartets and the risks of these 
diseases will be important for disease prevention and clin-
ical treatment. As we know, different definitions of MetS 
inevitably result in substantial confusion and absence of 
comparability between studies. Our study compares the 
differences of the ORs of MetS with CVD using different 
definitions and cut-offs, and we believe it is helpful in 
developing a generally accepted definition of MetS.
Some limitations of the study are worth mentioning. 
First of all, the study is a cross-sectional study and data 
could not be used for causal inference, which is a main 
limitation in epidemiological studies in general. Second, 
the diseases were self-reported, which may lead to misclas-
sification and underestimation of the association of MetS 
with the risk of diseases. However, previous studies have 
found that the associations of morbidity and mortality 
with self-reported AF were similar to those with electro-
cardiographically detected AF.34 35 In addition, although 
our analyses were conducted adjusting for smoking and 
alcohol consumption, some other lifestyle factors were 
still not included. Also, HDL cholesterol, triglyceride and 
blood glucose levels were measured only once, which 
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might be imprecise and result in random errors. Further-
more, the present study included only participants who 
had additional laboratory tests, and the association of 
MetS and CVD may be overestimated because high-risk 
CVD was more prevalent among them. Last but not least, 
the WHO definition and that of the European Group 
for the Study of Insulin Resistance were not used in the 
present study to define MetS for lack of assessment of 
impaired glucose or insulin resistance, which requires a 
more complicated test.
In summary, our findings indicate that MetS is signifi-
cantly associated with CVD in all the three definitions of 
MetS. The prevalence of CVD was more evident when 
MetS was defined according to the NCEP ATP III crite-
rion, compared with the updated IDF and AHA/NHLBI 
criteria. Among middle-aged and elderly Chinese popu-
lation, low HDL cholesterol and EBP are more prevalent 
than other components of MetS for ORs of CVD. Strat-
egies for the prevention and treatment of MetS should 
be developed and implemented to reduce the socioeco-
nomic and medical burden of CVD in China.
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